FDA panel urges Acrotech to speed up study on cancer drugs
The drugs, Folotyn and Beleodaq, have already been on the market for nearly a decade or more. "We would like the FDA and sponsor to strategize about other possible ways to have a shorter study readout than waiting another seven years from now," the panel's acting chairperson Andy Chen said on Thursday. The company's final study plan was submitted to the FDA in 2022 and is expected to be completed by 2030, according to FDA briefing documents published earlier this week.